$CNC

CENTENE CORPORATION REPORTS THIRD QUARTER 2026 RESULTS

Centene Corporation (CNC) reported Q3 2026 results with a GAAP loss of $(0.14) per share and adjusted EPS of $0.58. The company raised its 2026 EPS guidance, with GAAP EPS expected to exceed $3.46 and adjusted EPS to exceed $5.20. Centene also reduced debt by $1.1 billion, including full redemption of 2027 Senior Notes in October. The company's HBR improved to 92.7%, driven by the Medicare segment.

Original reporting
Published Oct 27, 2026, 10:00 AM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Oct 27, 2026, 10:04 AM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
CENTENE CORPORATION REPORTS THIRD QUARTER 2026 RESULTS — source image
Decision brief

The 30-second read

$CNCBullishHigh
01

Why it matters

The earnings beat and guidance raise suggest a short‑term rally, but cost pressures remain.

02

Market read

Centene's earnings beat and guidance lift are likely to move the stock and may influence peer valuations.

03

What to watch

Higher effective tax rate and rising SG&A could offset some upside.

Relevance 8/10Novelty 8/10Timing: today, after the Q3 release

Background

Centene is a large U.S. managed‑care company; Q3 earnings are a regular quarterly event.

Company-level read

Ticker impact

$CNCBullishHigh confidence
Context

Centene reported Q3 2026 results with GAAP loss per share of $0.14, adjusted EPS $0.58 and raised full‑year EPS guidance.

Expected impact

likely upward pressure as the market prices in higher EPS guidance

Evidence & confidence

Guidance increase of $0.40 for adjusted EPS and better HBR are material for a mid‑cap health insurer.

Market effects

May lift other managed‑care insurers as guidance beats expectations.

Positive for U.S. health‑care sector in the near term.

Limited to U.S. health‑care equities.

Counterpoint

If the guidance lift is already priced in, the stock could face a pull‑back on profit‑taking.

Key entities

  • Sarah M. London

    CEO of Centene, quoted on earnings performance.

Related articles

$CNCMedAI 8/10

What Centene (CNC) Said on Its Q3 Earnings Call

Centene (CNC) reported Q3 earnings, highlighting strong Medicare segment performance with a 93.8% HBR. The company raised its 2026 pre-tax margin forecast for PDP to mid-to-high 3% and expects Medicare Advantage break-even in 2026. Marketplace margins are improving, with a full-year 2026 pre-tax margin expected at the top of the 4.5%-5% range. Centene reduced debt to $15.0B and expects adjusted EPS growth in 2027.

$CNCHighAI 8/10

Centene (CNC) Q3 2026 Earnings Call Transcript

Centene (CNC) reported Q3 2026 earnings, highlighting a Medicaid HBR of 93.6, up 30 basis points from Q2. The company expects full-year Medicaid HBR of 93.5. Medicaid membership was in line with expectations, with a projected 8-9% year-end decline. Medicare Advantage and standalone Part D performed well, with Medicare Advantage on track for 2026 breakeven. Marketplace business is expected to produce a full-year pretax margin at the top of the 4.5% to 5.0% range.

$CNCMed

Centene Corporation Q3 2026 Earnings Call Summary

Centene Corporation reported Q3 2026 earnings, highlighting Medicare Advantage breakeven, Medicaid stability, and Marketplace margin recovery. The company reduced debt to $15.0 billion and expects 2027 adjusted EPS growth. Management plans to exit less profitable areas and optimize costs. Medicaid membership is declining, and Marketplace enrollment may contract in 2027. Non-recurring benefits added $0.50 per share in 2026.

$CNCMed

Centene progresses on profit recovery, drops 6,000 employees

Centene reported Q3 revenue of $50.6B, up 2% YoY, and narrowed losses to $71M. The company raised its 2026 earnings outlook due to Medicare Advantage cost reductions, now expecting to break even in the segment. Centene also announced layoffs and voluntary separations, reducing its workforce by 6,000 employees, which is expected to improve margins in 2027. The company's medical loss ratio was 92.7%, slightly better than expected.